Haloperidol Depot Hikma (Haloperidol Decanoate)

Haloperidol Depot Hikma is indicated for the treatment of several psychotic disorders where long‑acting antipsychotic coverage is desired.

• Schizophrenia, including acute exacerbations and maintenance therapy.
• Acute psychosis requiring rapid symptom control.
• Chronic psychotic disorders where oral adherence is challenging.
• Adjunctive stabilization after hospitalization for psychotic episodes.
• Long‑term maintenance to reduce relapse risk in patients stabilized on haloperidol.

Side effects of haloperidol decanoate depot injections vary in frequency and severity; they are grouped here for clarity.

Common

• Sedation or drowsiness.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, potentially irreversible involuntary movements.
• Significant cardiac effects, including QT interval prolongation.

When prescribing Haloperidol Depot Hikma, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiovascular status, especially for QT prolongation risk.
• Monitor for signs of extrapyramidal reactions and tardive dyskinesia.
• Use caution in patients with a history of seizures or neuroleptic malignant syndrome.
• Evaluate liver and renal function before initiating therapy.
• Adjust dosing in elderly patients or those with frailty.
• Discuss pregnancy and lactation considerations with women of child‑bearing potential.

Haloperidol decanoate can interact with other medicines; understanding these interactions helps prevent adverse outcomes.

Avoid

• Other dopamine antagonists or high‑potency antipsychotics that may increase extrapyramidal risk.
• Medications that markedly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inducers that could reduce haloperidol levels (e.g., rifampin, carbamazepine).

Use with caution

• CNS depressants such as benzodiazepines or opioids, which may enhance sedation.
• Anticholinergic agents that can mask extrapyramidal symptoms.
• Lithium, due to potential additive neurotoxic effects.